GMGaëtan MacGrogan

Gaëtan MacGrogan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gaëtan MacGrogan has a total of 187 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validation of death prediction after breast cancer relapses using joint models

    by Audrey Mauguen, Bernard Rachet, Simone Mathoulin-Pélissier, Gill M Lawrence, Sabine Siesling, Gaëtan MacGrogan, Alexandre Laurent, Virginie Rondeau

    Cancer relapses may be useful to predict the risk of death. To take into account relapse information, the Landmark approach is popular. As an alternative, we propose the joint frailty model for a recurrent event and a terminal event to derive dynamic predictions of the risk of death. The proposed prediction settings can account for relapse history or not. In this work, predictions developed on a French hospital series of patients with breast cancer are externally validated on UK and Netherlands registry data. The performances in terms of prediction error and calibration are compared to those from a Landmark Cox model. The error of prediction was reduced when relapse information was taken into account. The prediction was well-calibrated, although it was developed and validated on very different populations. Joint modelling and Landmark approaches had similar performances. When predicting the risk of death, accounting for relapses led to better prediction performance. Joint modelling appeared to be suitable for such prediction. Performance was similar to the landmark Cox model, while directly quantifying the correlation between relapses and death.


  • Open Access

    SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases

    by Jocelyne Jacquemier, Frédérique Spyratos, Benjamin Esterni, Marie-Joëlle Mozziconacci, Martine Antoine, Laurent Arnould, Sarab Lizard, Philippe Bertheau, Jacqueline Lehmann-Che, Cécile Blanc Fournier, et al.

    Until now, FISH has been the gold standard technique to identify HER2 amplification status in ambiguous cases of breast cancer. Alternative techniques have been developed to increase the capacities of investigating HER2 amplification status. The aims of this multicenter study in a large series of breast cancer patients were to prospectively compare the level of performance of CISH, SISH, and qPCR alternative techniques on paraffin-embedded core biopsies with “gold standard FISH” for evaluation of HER2 amplification status. This study was performed on 840 cases scored by immunohistochemistry (IHC): 0=317 (38%), 1+=183 (22%), 2+=109 (13%), 3+=231 (27%). Each of the 15 French centers participating in the study analyzed 56 breast carcinoma cases diagnosed on fixed paraffin-embedded core biopsies. HER2 amplification status was determined by commercially available FISH used as the reference technique with determination of the HER2/CEN17 ratio or HER2 copy number status. The alternative techniques performed on the same cases were commercially available SISH or CISH and a common qPCR method especially designed for the study including a set of 10 primer pairs: 2 for HER2 (exons 8 and 26), 5 to evaluate chromosome 17 polysomy TAOK1, UTP6, MRM1, MKS1, SSTR2 and 3 for diploidy control TSN, LAP3 and ADAMTS16. The concordance between IHC and FISH was 96% to 95% based on the HER2/CEN17 ratio (n=766) or HER2 copy number (n=840), respectively. The concordance of the alternative techniques with FISH was excellent: 97% and 98% for SISH (498 and 587 cases), 98% and 75% for CISH (108 and 204 cases) and 95% and 93% (699 and 773 cases) for qPCR based on the HER2/CEN17 ratio or HER2 copy number, respectively. Similarly, sensitivity ranged from 99% to 95% for SISH, 100% to 99% for CISH and 89% to 80% for qPCR. The concordance with FISH (ratio) in the 2+ cases was 89% for SISH, 100% for CISH and 93% for qPCR. These alternative techniques showed an excellent concordance with FISH in core biopsies allowing their use in routine clinical practice. This newly designed qPCR on paraffin-embedded core biopsies deserves special attention, as it is reliable, easy to perform and less expensive than ISH tests.


  • Open Access

    An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis

    by Françoise Bonnet, Mickael Guedj, Natalie Jones, Sana Sfar, Véronique Brouste, Nabila Elarouci, Guillaume Banneau, Béatrice Orsetti, Charlotte Primois, Christine Tunon de Lara, et al.

    Background: Despite entering complete remission after primary treatment, a substantial proportion of patients with early stage breast cancer will develop metastases. Prediction of such an outcome remains challenging despite the clinical use of several prognostic parameters. Several reports indicate that genomic instability, as reflected in specific chromosomal aneuploidies and variations in DNA content, influences clinical outcome but no precise definition of this parameter has yet been clearly established. Methods: To explore the prognostic value of genomic alterations present in primary tumors, we performed a comparative genomic hybridization study on BAC arrays with a panel of breast carcinomas from 45 patients with metastatic relapse and 95 others, matched for age and axillary node involvement, without any recurrence after at least 11 years of follow-up. Array-CGH data was used to establish a two-parameter index representative of the global level of aneusomy by chromosomal arm, and of the number of breakpoints throughout the genome. Results: Application of appropriate thresholds allowed us to distinguish three classes of tumors highly associated with metastatic relapse. This index used with the same thresholds on a published set of tumors confirms its prognostic significance with a hazard ratio of 3.24 [95CI: 1.76-5.96] p = 6.7x10-5 for the bad prognostic group with respect to the intermediate group. The high prognostic value of this genomic index is related to its ability to individualize a specific group of breast cancers, mainly luminal type and axillary node negative, showing very high genetic instability and poor outcome. Indirect transcriptomic validation was obtained on independent data sets. Conclusion: Accurate evaluation of genetic instability in breast cancers by a genomic instability index (G2I) helps individualizing specific tumors with previously unexpected very poor prognosis.


  • Open Access

    Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: recurrence, metastases, second cancer and death

    by Virginie Rondeau, Simone Mathoulin-Pélissier, Lucie Tanneau, Annie J Sasco, Gaétan MacGrogan, Marc Debled

    In the setting of recurrent events, research studies commonly count only the first occurrence of an outcome in a subject. However this approach does not correctly reflect the natural history of the disease. The objective is to jointly identify prognostic factors associated with locoregional recurrences (LRR), contralateral breast cancer, distant metastases (DM), other primary cancer than breast and breast cancer death and to evaluate the correlation between these events.


  • Delineation of molecular subgroups of breast cancer with distinct genomic profiles and different clinical courses: a novel definition of disease subclasses

    by C. Theillet, M. Guedj, L. Marisa, A. de Reynies, B. Orsetti, R. Schiappa, F. Bibeau, M. Longy, G. Macgrogan, F. Lerebours, et al.

  • Open Access

    Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations

    by Guillaume Banneau, Mickaël Guedj, Gaëtan MacGrogan, Isabelle de Mascarel, Valerie Velasco, Renaud Schiappa, Valerie Bonadona, Albert David, Catherine Dugast, Brigitte Gilbert-Dussardier, et al.

    Introduction: Breast carcinoma is the main malignant tumor occurring in patients with Cowden disease, a cancer-prone syndrome caused by germline mutation of the tumor suppressor gene PTEN characterized by the occurrence throughout life of hyperplastic, hamartomatous and malignant growths affecting various organs. The absence of known histological features for breast cancer arising in a PTEN-mutant background prompted us to explore them for potential new markers. Methods: We first performed a microarray study of three tumors from patients with Cowden disease in the context of a transcriptomic study of 74 familial breast cancers. A subsequent histological and immunohistochemical study including 12 additional cases of Cowden disease breast carcinomas was performed to confirm the microarray data. Results: Unsupervised clustering of the 74 familial tumors followed the intrinsic gene classification of breast cancer except for a group of five tumors that included the three Cowden tumors. The gene expression profile of the Cowden tumors shows considerable overlap with that of a breast cancer subgroup known as molecular apocrine breast carcinoma, which is suspected to have increased androgenic signaling and shows frequent ERBB2 amplification in sporadic tumors. The histological and immunohistochemical study showed that several cases had apocrine histological features and expressed GGT1, which is a potential new marker for apocrine breast carcinoma. Conclusions: These data suggest that activation of the ERBB2-PI3K-AKT pathway by loss of PTEN at early stages of tumorigenesis promotes the formation of breast tumors with apocrine features.


  • Open Access

    Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer

    by Carine A Bellera, Gaëtan MacGrogan, Marc Debled, Christine Tunon de Lara, Véronique Brouste, Simone Mathoulin-Pélissier

    The Cox model relies on the proportional hazards (PH) assumption, implying that the factors investigated have a constant impact on the hazard - or risk - over time. We emphasize the importance of this assumption and the misleading conclusions that can be inferred if it is violated; this is particularly essential in the presence of long follow-ups.


  • Variables with time-varying effects and the Cox model: Illustration with the role of estrogen receptor status in breast cancer

    by C. A. Bellera, G. MacGrogan, M. Debled, C. Tunon de Lara, V. Brouste, S. Mathoulin-Pélissier

    6584 Background: The Cox proportional hazards model allows one to estimate the effect of factors influencing a time-to- event or survival time. This model, however, relies on a fundamental assumption, the proportionality of the hazards (PH): given two individuals with distinct values for a specific factor, the ratio of the estimated hazards is constant over time. A typical example in the genral population is the effect of age on the survival time following surgery. If age is more likely to impact the survival immediately after surgery than weeks or months later, then the PH hypothesis would not hold, and thus misleading effect estimates could be derived. Altman et al. showed that the majority of cancer publications do not report verifying this crucial assumption. Methods: We emphasize the importance of the assumption of the Cox model, and the misleading conclusions that can be inferred if it is violated. We recall that the hazard ratio (HR) provided by the Cox model is a time-averaged hazard ratio. If the HR changes over time, this time-averaged HR might not be representative of the true effect. Results: We illustrate our discussion by analyzing time to metastases in 855 women treated with surgery for a primary breast cancer, with the following prognostic factors: age, tumor size, SBR grade, vascular emboli, lymph node involvement, estrogen (ER) and progesterone receptor status, Her2 status, Mib1 proliferation index. The median follow-up time was 11 years, and there were 216 relapses. While ER was not significantly associated with the time to metastases in the initial Cox model, further analyses showed that ER effect was not constant over time. On average over the study follow-up, ER is not associated with time to metastases, but given the non constant HR, ER may have an impact over some specific periods of time. Conclusion : Our example illustrates that misleading conclusions can be inferred when one ignores the PH assumption. We provide statistical elements the reader should look for when reviewing clinical publications relying on a Cox model; this is particularly important when the follow-up period is long. No significant financial relationships to disclose.